Imbruvica and Mucosal dryness - a phase IV clinical study of FDA data

Summary:

Mucosal dryness is reported as a side effect among people who take Imbruvica (ibrutinib), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Venclexta, and have Chronic lymphocytic leukaemia.

The phase IV clinical study analyzes which people have Mucosal dryness when taking Imbruvica. It is created by eHealthMe based on reports of 69,938 people who have side effects when taking Imbruvica from the FDA, and is updated regularly.

What is Imbruvica?

Imbruvica has active ingredients of ibrutinib. It is often used in chronic lymphocytic leukemia (cll). eHealthMe is studying from 70,020 Imbruvica users. Check the latest studies of Imbruvica.

What is Mucosal dryness?

Mucosal dryness (dryness of mucous membrane) is found to be associated with 362 drugs and 468 conditions by eHealthMe. Check the latest studies of Mucosal dryness.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

69,938 people reported to have side effects when taking Imbruvica.
Among them, 11 people (0.02%) have Mucosal dryness.

Among these 11 people:

How long have people been on Imbruvica when they have Mucosal dryness? *

What is the gender of people who have Mucosal dryness when taking Imbruvica? *

female: 72.73 %
male: 27.27 %

What is the age of people who have Mucosal dryness when taking Imbruvica? *

What are other drugs people take besides Imbruvica? *

What are other side effects people have besides Mucosal dryness? *

Red Blood Cell Count Decreased: 8 people, 72.73%
Thrombocytopenia (decrease of platelets in blood): 8 people, 72.73%
Hair Loss: 8 people, 72.73%
The Flu (the flu is caused by an influenza virus): 8 people, 72.73%
Dry Mouth: 8 people, 72.73%
Migraine (headache): 7 people, 63.64%
Hypotension (abnormally low blood pressure): 6 people, 54.55%
Muscle Aches (muscle pain): 6 people, 54.55%
Dizziness: 6 people, 54.55%
Deafness Neurosensory: 6 people, 54.55%

What are the existing conditions these people have? *

Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 11 people, 100.00%
Tonsillitis (inflammation of tonsil): 5 people, 45.45%
Thyroid Diseases: 5 people, 45.45%
Sleep Disorder: 5 people, 45.45%
Pain: 5 people, 45.45%
Depression: 5 people, 45.45%

* Approximation only. Some reports may have incomplete information.

Do you take Imbruvica and have Mucosal dryness?

- Check whether Mucosal dryness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Imbruvica:

Imbruvica (70,020 reports)

Mucosal dryness treatments and more:

Mucosal dryness (2,332 reports)

Browse all side effects of Imbruvica:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Mucosal dryness:

Mucosal dryness (362 drugs)

Browse all the conditions that are associated with Mucosal dryness:

Mucosal dryness (468 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ibrutinib (the active ingredients of Imbruvica) and Imbruvica (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.